SequelSEC

Scilex Holding Co SCLX

Biological Products, (No Diagnostic Substances) · CIK 0001820190 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$30.25M
Fiscal year ended 2025-12-31
Operating income
-$346.01M
Fiscal year ended 2025-12-31
Free cash flow
$3.68M
Fiscal year ended 2025-12-31

Scilex Holding Co (SCLX) reported revenue of $30.25M and net income of -$374.05M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Scilex Holding Co’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Scilex Holding Co income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$30.25M$56.59M$46.74M$38.03M$31.32M$23.56M
Cost of revenueUnavailableUnavailable$15.68M$10.80M$3.63M$2.15M
Gross profitUnavailableUnavailable$31.06M$27.24M$27.68M$21.41M
Operating income-$346.01M-$83.40M-$105.43M-$50.63M-$35.84M-$35.26M
Net income-$374.05M-$72.81M-$114.33M-$23.36M-$88.42M-$47.52M
Research & development$20.71M$9.64M$12.75M$9.05M$9.20M$9.96M
Weighted-average diluted sharesUnavailableUnavailableshares 130.30Mshares 134.23Mshares 132.86MUnavailable
Pretax income-$374.03M-$72.81M-$114.32M-$23.36M-$88.42M-$47.57M
Income tax expense$26.00K-$1.00K$13.00K$4.00K$5.00K-$53.00K
Diluted EPS$-36.48$-8.05$-1.28$-0.17$-0.67$-0.36
Selling, general & administrative$266.88M$119.02M$119.64M$64.90M$50.58M$42.97M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Scilex Holding Co balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$4.96M$3.27M$3.92M$2.18M$4.34M$30.51K
Total assets$364.98M$92.95M$101.31M$86.53M$77.93M$199.48K
Current assets$38.36M$41.55M$46.78M$29.61M$23.00M$30.51K
Total liabilities$576.73M$285.59M$274.25M$50.29M$301.81M$180.76K
Current liabilities$483.65M$259.64M$250.38M$44.84M$169.42M$180.76K
Total equity incl. NCI-$211.75M-$192.64M-$172.94M$36.24M-$223.88M-$141.68M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$139.38MUnavailable
Inventory$4.79M$2.44M$4.21M$1.38M$2.56MUnavailable
Accounts receivable$15.24M$26.44M$34.60M$21.24M$14.27MUnavailable
Goodwill$13.48M$13.48M$13.48M$13.48M$13.48MUnavailable
Long-term debtUnavailableUnavailableUnavailable$0$72.04MUnavailable
Accounts payable$86.27M$52.62M$40.95M$8.45M$4.28MUnavailable

Cash flow

Scilex Holding Co cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow$3.82M$19.35M-$20.71M-$21.26M-$28.66M-$31.46M
Capital expenditures$133.00K$0$30.00K$7.00K$0$25.00K
Investing cash flow$4.08M-$2.68M-$330.00K-$2.07M$0-$25.00K
Financing cash flow-$5.46M-$18.13M$23.58M$21.17M$28.16M-$19.17M
Net change in cash$1.68M-$1.46M$2.54M-$2.15M-$501.00K-$50.66M
Stock-based compensation$15.49M$15.69M$14.60M$5.28M$5.82M$5.40M
Common dividends paidUnavailable$8.65M$8.65MUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.62M$4.05M$4.15M$3.96M$3.78M$3.78M

Derived

Scilex Holding Co derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow$3.68M$19.35M-$20.74M-$21.26M-$28.66M-$31.49M
Gross margin415.8%295.8%66.5%71.6%88.4%90.9%
Operating margin-1143.7%-147.4%-225.6%-133.1%-114.4%-149.7%
FCF margin12.2%34.2%-44.4%-55.9%-91.5%-133.6%
SBC / revenue51.2%27.7%31.2%13.9%18.6%22.9%
Current ratio0.08x0.16x0.19x0.66x0.14x0.17x
Revenue YoY growth-46.5%21.1%22.9%21.4%32.9%Unavailable
Net margin-1236.4%-128.7%-244.6%-61.4%-282.4%-201.7%
R&D / revenue68.5%17.0%27.3%23.8%29.4%42.3%
CapEx / revenue0.4%0.0%0.1%0.0%0.0%0.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SCLX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-10View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

balance equationreview2021-12-31

Difference 139380000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2020-12-31

Difference 141701724 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.